knowledge -WSS

knowledge

author：explore 2025-09-30 22:04:22 - browse：3

Stoke Therapeutics is still seeking an effective dose for an experimental drug to treat a severe form of childhood epilepsy, following the release of updated data Tuesday that showed disappointing reductions in convulsive seizure activity.

In the latest look at an ongoing mid-stage study, three monthly injections of the Stoke drug, called STK-001, given at a 45-mg dose, resulted in a median 18% reduction in convulsive seizure activity, compared to baseline.

The new analysis was conducted on 16 children diagnosed with a rare form of epilepsy called Dravet syndrome. Last November, in six patients, the drug showed a median 55% reduction in seizure activity.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Surge in Apellis stock fueled by confidence in safety of its eye drug

focus

WSS

Biogen’s boardroom scandal saddles CEO with first crisis

Bird flu researchers hone in on Finland’s mink farms

Covid isolation guidance eased by the CDC

Obesity now affects over 1 billion people worldwide, study finds

Yogurt drink instead of a colonoscopy? CRISPR bacteria are tested

Maui wildfire now ranks as the fifth

Wikipedia

knowledge

knowledge

BioMarin wins approval for gene therapy to treat hemophilia A

Flu vaccine offering decent levels of protection this winter, new data show

Moonlake's readout produced a cash windfall. Risks remain

How to address the problem of discarded donor organs

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Covid isolation guidance eased by the CDC

Wildfire smoke exposes gaps in outdoor worker protections

RSV vaccines may be linked to small increased risk of developing GBS

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Scientists unlock the key to scar

explore

Novo Nordisk touts Wegovy study, but still struggling with supply

RSV vaccines may be linked to small increased risk of developing GBS

A Q&A with Aletha Maybank, AMA’s chief health equity officer

Biogen’s boardroom scandal saddles CEO with first crisis

Judge sides with young activists in first

Surge in Apellis stock fueled by confidence in safety of its eye drug

leisure time

focus

knowledge

explore